The U.S. Federal Trade Commission issued an order preventing TA Sciences from advertising products containing cycloastragenol as "anti-aging". [1] A single in vitro study on human CD4 and CD8 T cells led to claims that cycloastragenol may activate telomerase, leading to controversial claims for its role in reducing the effects of aging.[2]

History[edit]

Cycloastragenol was studied by Geron Corporation and sold to T.A. Sciences in early 2013 who are developing it as a product named TA-65. Bill Andrews of Sierra Sciences has done testing on the anti-aging aspect of TA-65;[3][unreliable source?], as well as Maria Blasco in the journal Aging Cell, finding no increase in murine median or mean lifespan but some physiological anti-aging effects without augmenting cancer incidence.[4]

In late 2013, dietary supplement company RevGenetics released their conclusions on TA-65 that showed it is the single molecule cycloastragenol used in TA-65.[5] More recently, on May 15, 2014 RevGenetics released a press release where they provide new information about a public UK government application where TA Sciences state (among other things) that the active ingredient in TA-65 is cycloastragenol.[6]